PHILADELPHIA — Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology — "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy." Cancer immunology is a field of research that explores the complex relationship between cancer and the immune system, with the goal of discovering immune-based solutions to curing cancer.
The SU2C-CRI Cancer Immunology Translational Research Dream Team will receive $10 million in funding over three years for this translational cancer research project that will unite laboratory and clinical efforts leading to the immunological treatment, control and prevention of cancer.
The team will be led by James P. Allison, Ph.D., and Antoni Ribas, M.D., Ph.D. Allison is chairman of the department of immunology, director of the immunotherapy platform and co-director of the David H. Koch Center for Applied Research of Genitourinary Cancers at The University of Texas MD Anderson Cancer Center. Ribas is professor of medicine, surgery and molecular and medical pharmacology, director of the tumor immunology program area at the Jonsson Comprehensive Cancer Center, and member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles (UCLA).
"The goal of our Dream Team is to expand, optimize and explore combinations of two novel immunotherapies, immune checkpoint blockade and adoptive T-cell transfer," said Allison. "It is our dream, indeed our expectation, that by optimizing these two uniquely successful and complementary approaches, we will be able achieve durable responses in a large percentage of patients suffering from a variety of types of cancer."
"The SU2C-CRI Dream Team brings together a leading group of tumor immunologists working to speed up the pace of scientific advances to use the immune system to fight cancer," said Ribas.
Co-leaders of the Dream Team are Drew M. Pardoll, M.D., Ph.D., and Cassian Yee, M.D. Pardoll is director of the division of immunology and Abeloff professor in the departments of oncology, medicine, pathology and molecular biology and genetics at the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University in Baltimore, Md. Yee is a member of the Clinical Research Division and program in immunology at Fred Hutchinson Cancer Research Center; a professor of medicine at the University of Washington School of Medicine; and an attending physician at the Seattle Cancer Care Alliance in Seattle, Wash.
Scientists on this Dream Team represent eight institutions: MD Anderson Cancer Center, UCLA, The Johns Hopkins University, Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, California Institute of Technology, Memorial Sloan-Kettering Cancer Center and the Netherlands Cancer Institute.
"The clinical advances in immunotherapy just in the past two years have shown that these strategies indeed empower the patient's own immune system to successfully fight their cancer. Single interventions opened the door; the future is combinatorial therapy, and the synergistic expertise of our Dream Team will catalyze the development of the most innovative combinations," said Pardoll.
"Adoptive T cell therapy in recent years has really come into its own. Novel strategies to generate long-lasting, highly effective T cells are being developed, and in combination with new immunomodulatory agents like the checkpoint inhibitors, we can fully exploit the immune system to treat patients with cancer. We are so fortunate to now have the opportunity to explore these new frontiers in immunotherapy," said Yee.
Significant scientific developments in the field of cancer immunology and the recent FDA approvals of two cancer immunotherapies highlight the field's potential to transform cancer treatment. The formation of this Dream Team focused on this promising area of cancer research aligns with CRI's 60-year mission to advance cancer immunology and SU2C's mission to accelerate the translation of scientific discovery into new treatments for cancer patients.
"Because of my deep respect for the innovative approach to cancer research taken by Stand Up To Cancer, I wanted to support the creation of a team dedicated to this emerging area of research," said tech entrepreneur and philanthropist Sean Parker. "I am delighted that SU2C and the Cancer Research Institute have combined their expertise to select a Dream Team with such great potential to move the field forward through cutting-edge technology and science."
"Cancer immunology, a field which the Cancer Research Institute pioneered and has led for sixty years, is a high-potential area of medical research that is producing some of today's greatest breakthroughs in cancer patient treatment, and I am confident that this Dream Team is going to succeed in making the next great advance," said Jill O'Donnell-Tormey, Ph.D., chief executive officer and director of scientific affairs at CRI.
"Stand Up To Cancer is excited to make this investment in exploring strategies that can activate and enhance the body's own natural ability to fight cancer. The field of cancer immunology is ripe with possible breakthroughs that could change the landscape of cancer treatment, and thus perfectly suited to Stand Up To Cancer's mission to accelerate research that can make more cancer patients survivors," said Sherry Lansing, SU2C co-founder, founder of the Sherry Lansing Foundation, and chairperson of the Entertainment Industry Foundation's (EIF) Board of Directors. (SU2C is a program of EIF, which is a 501(c)3 charitable organization.)
"Along with collaboration, innovation is a pillar of SU2C's model of cancer research, and we are incredibly grateful to have the support of a true innovator in the world of technology like Sean Parker," said SU2C Co-founder Rusty Robertson. "With this immunology-focused Dream Team, we have the opportunity to utilize Sean Parker's generous contribution to advance a cutting-edge field that holds great potential to save lives."
The SU2C-CRI Cancer Immunology Translational Research Project
Cancer immunologists have long hypothesized that specific interventions could stimulate and "re-educate" patients' own immune systems to attack their cancer. In one immunology-based cancer treatment approach, what kills cancer cells is a type of white blood cell called the T lymphocyte. Expanding these T lymphocytes outside the body, engineering them to be more potent and reinfusing these souped up anti-cancer lymphocytes into patients – a process termed adoptive cell therapy or ACT – is like adding more soldiers to the immune army. However, lymphocytes also have inhibitory receptors, termed checkpoints, that put the brakes on immune responses. Cancers exploit these checkpoints to resist immune attack by the anti-tumor lymphocytes. Blocking checkpoints with specific antibodies disables the brake and allows the immune system to get the upper hand.
The Dream Team will focus on two approaches to overcome these obstacles. First, they will investigate checkpoint blockade, where the checkpoints themselves are inhibited using antibodies, once again allowing T lymphocytes to kill the cancer cells. Second, the team will pursue multiple ACT approaches.
Using tumors obtained from patients, the team will evaluate checkpoint expression before and after ACT and/or checkpoint blockade, and will test the hypothesis that multiple T lymphocyte targets are generated in the tumor. The clinical impact of this project lies with the potential synergy of combining these two immunology-based therapeutic approaches to treat a range of tumor types to improve the lives of patients with cancer.
The project is estimated to start in the spring of 2013, with the first clinical trials scheduled to open in early 2014.
Dream Team Selected Through Unique, Rigorous Process
A SU2C-CRI Joint Scientific Advisory Committee (JSAC) conducted a unique, interactive, rapid and rigorous evaluation of the applications using a multi-step scientific review process. The JSAC is composed of highly accomplished senior laboratory researchers and physician-scientists, as well as patient advocates.
The committee is chaired by Nobel laureate Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. It is co-chaired by Giorgio Trinchieri, M.D., and Carl H. June, M.D. Trinchieri is director of the Cancer and Inflammation Program and chief of the Laboratory of Experimental Immunology at the Center for Cancer Research, National Cancer Institute, and associate director for basic science at the Trans-NIH Center for Human Immunology. June is director of translational research at the Abramson Cancer Center at the University of Pennsylvania, and is an investigator with the Abramson Family Cancer Research Institute. He is also a professor in the department of pathology and laboratory medicine.
The review process began with a call for letters of intent in March of 2012 by the American Association for Cancer Research (AACR), SU2C's scientific partner. The committee then chose four finalist teams, each of which met in person with the JSAC to present plans for their research and respond to questions about their projects – a level of interaction between applicants and reviewers that is unique among scientific review processes.
The AACR is responsible for administering the grant and provides ongoing scientific oversight to ensure that progress is being made. Since the launch of Stand Up To Cancer, the AACR has played an integral role as SU2C's scientific partner by providing scientific leadership, expert peer review and grants administration.
Dream Team Principals and Advocate Members
The "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy" Dream Team consists of a multidisciplinary group of experts that includes laboratory and clinical researchers, young investigators and senior scientists who have not worked together in the past, as well as patient advocates. Besides Allison, Ribas, Pardoll and Yee, team members include:
Since Stand Up To Cancer's launch in 2008, SU2C has awarded grants to nine Dream Teams and one International Translational Cancer Research Grant. Twenty-six Innovative Research Grants have been awarded to individual young investigators. These recipients comprise more than 450 scientists from 87 institutions.
About Stand Up To Cancer
Stand Up To Cancer (SU2C) — a program of the Entertainment Industry Foundation (EIF), a 501(c)3 charitable organization — raises funds to hasten the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. In the fall of 2007, a group of women whose lives have all been affected by cancer in profound ways began working together to marshal the resources of the media and entertainment industries in the fight against this disease.
Members of the SU2C Executive Leadership Council (ELC) include Talk Show Host, Journalist and well-known Cancer Advocate Katie Couric; Sherry Lansing, Chairperson of the Entertainment Industry Foundation's Board of Directors and founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; EIF Senior Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; Pamela Oas Williams, President of Laura Ziskin Productions and Executive Producer of Stand Up To Cancer's In-House Production Team, and Nonprofit Executive Ellen Ziffren. All of the ELC members were co-producers of the 2012 televised special. The late Laura Ziskin, executive producer of both the Sept. 5, 2008 and Sept. 10, 2010 broadcasts, was also a member of the ELC. SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C's president and CEO since 2011.
SU2C's "Dream Team" approach to funding translational cancer research enables scientists from different disciplines at research centers across the country and internationally to collaborate on projects geared toward getting new, less toxic treatments to patients as quickly as possible. Monies also support innovative cancer research projects that are often deemed "too risky" by conventional funding sources. Sixty-five institutions are currently involved. As SU2C's scientific collaborator, the American Association for Cancer Research, led by a prestigious SU2C Scientific Advisory Committee, provides scientific oversight, expert review of the research projects and grants administration. For more information, visit standup2cancer.org.
About the Cancer Research Institute
The Cancer Research Institute (CRI), a nonprofit established in 1953, is the global leader in cancer immunology. Since its inception, CRI has invested hundreds of millions of dollars to support research conducted by more than 3,000 scientists and clinicians worldwide to understand the immune system and how it can be harnessed to conquer all cancers. This work has laid the foundation for nearly every major cancer immunotherapy breakthrough over the past half century.
Guided by an international panel of the world's leading immunologists and cancer immunologists, including three Nobel laureates and 29 members of the U.S. National Academy of Sciences, CRI provides essential funding to support every stage of discovery, from laboratory investigation to clinical trials of the most promising cancer immunotherapies for patients.
CRI also sponsors a seminal international symposium on cancer immunology each year, hosts annual scientific colloquia dedicated to overcoming challenges in immunotherapy research and development, forges collaborative partnerships between academia and industry to facilitate the development pathway for novel immunotherapeutics, and presents special recognition awards to individuals who have made outstanding contributions to cancer research, patient care and public awareness.
Through its sustaining support and leadership in the field, CRI is accelerating the development of safe and effective immunotherapies that stand to revolutionize the treatment of all cancers. For more information, visit http://cancerresearch.org or follow CRI on Twitter @CancerResearch.
About the American Association Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional association dedicated to advancing cancer research and preventing and curing cancer. AACR membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org. Follow the AACR on Twitter: @aacr #aacr. Follow the AACR on Facebook: http://www.facebook.com/aacr.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.